CHANGZHOU, China--(BUSINESS WIRE)--China Kanghui Holdings (NYSE: KH - News) (“Kanghui” or the “Company”), a leading domestic developer, manufacturer and marketer of orthopedic implants in China, today announced that its initial public offering of 6,675,000 American Depositary Shares (“ADSs”), representing 40,050,000 ordinary shares, was priced at $10.25 per ADS. The Company is offering 5,340,000 ADSs, and the selling shareholders are offering 1,335,000 ADSs. The ADSs are expected to begin trading on the New York Stock Exchange on August 11, 2010 under the symbol “KH.”

The Company has granted the underwriters a 30-day option to purchase up to 1,001,250 additional ADSs.

The Company intends to use the net proceeds for the development of its product pipeline, expansion of its manufacturing capacities, enhancement of its sales and marketing capabilities as well as general corporate purposes.

Morgan Stanley and Piper Jaffray are acting as the joint book running managers of the offering. Cowen and Company and Canaccord Genuity are acting as co-managers.

Kanghui’s registration statement relating to these securities was declared effective on August 10, 2010 by the U.S. Securities and Exchange Commission. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

A copy of the prospectus related to the offering may be obtained by contacting Morgan Stanley & Co. Incorporated, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York, 10014, telephone: 1 (866) 718-1649, or by e-mailing prospectus@morganstanley.com or by contacting Piper Jaffray & Co., Prospectus Department, 800 Nicollet Mall, Suite 800, Minneapolis, Minnesota 55402, telephone: 1 (612) 303-8290 or by email: prospectus@pjc.com.

About China Kanghui Holdings

Founded in 1997, Kanghui is a leading domestic developer, manufacturer and marketer of orthopedic implants in China. The Company offers a wide array of proprietary orthopedic implant products in trauma and spine. It has an extensive network of distributors for its products in China. In addition, Kanghui’s products are distributed in 24 countries. Kanghui has strong research and development capabilities, focused on developing new proprietary products, including new product lines, extensions of existing product lines and enhancements of existing products. For more information, please visit www.kanghui.com

Contact:

Kanghui Investor Relations Department

646-416-6822

or

ICR, LLC

In the U.S.:

Ashley M. Ammon and Christine Duan, 1-646-277-1227

or

In China:

Wen Lei Zheng, 86-10-6599-7968